A Dx Puzzle is Solved: Beckman Acquires Hybritech
Executive Summary
Eli Lilly’s sale of Hybritech to Beckman Instruments marks the end of the pharmaceutical company’s rocky foray into diagnostics.
You may also be interested in...
Beckman Coulter's Play for High Growth
With the Coulter integration successful, Beckman Coulter looks for high-growth opportunities outside of its traditional businesses. Beckman, through internal efforts in its life sciences business and a series of small alliances, is making a play in genomics and proteomics. In addition to building up near-term revenues, the aim is to find new "content" in the form of assays for its clinical business.
FDA Advisory Committees Continue To Come Under Congressional Scrutiny
Rep. Anna Eshoo, the ranking Democrat on the House Energy and Commerce health subcommittee suggested FDA and CDC vaccine advisory committees contributed to the public’s confusion during the pandemic response.
Chinese Companies Progress Peptide Fusion Inhibitors For COVID-19
China's Hybio, Youcare and Shanxi Jinbo appear to be the only three companies in the world trying to develop a fusion inhibitor for COVID-19, the most advanced of which has now moved into a domestic Phase II trial.